Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives

A compound or pharmaceutically acceptable salt or solvate of Formula (I),

• wherein:
• X is C or N;
• R1 is selected from an aryl or
• wherein ring A is a 5 to 6 membered heterocyclyl containing Z, wherein Z is an O, S or N heteroatom which is adjacent to the point of attachment, and wherein R1 is optionally further substituted with 0 to 3 R9 groups and wherein two of the R9 groups may optionally cyclize to form an aryl or a 5-6 membered heterocyclyl ring containing N or S fused to the aryl or heterocyclyl to which it is attached;
• R2 is H or C1-C6 alkyl optionally further substituted with 0 to 3 R9 groups;
• R3 may be attached to any unsaturated carbon on the ring and is selected from H, C1-C6alkyl or halide, or perfluoroalkyl;
• R4 and R5 are each independently selected from H, Ra—O—Rb, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, —(Rd)m—(C3-C12 cycloalkyl), —(Rd)m-aryl, —(Rd)m-(3-15 membered heterocyclyl), —(Rd)m—(C1-C6 perfluoroalkyl), —(Rd)mhalide, —(Rd)m—CN, —(Rd)m—C(O)Ra, —(Rd)m—C(O)ORa, —(Rd)m—C(O)NRaRb, —(Rd)m—ORa, —(Rd)m—OC(O)Ra, —(Rd)m—OC(O)NRaRb, —(Rd)m—O—S(O)Ra, —(Rd)m—OS(O)2Ra, —(Rd)m—OS(O)2NRaRb, —(Rd)m—OS(O)NRaRb, —(Rd)m—NO2, —(Rd)m—NRaRb, —(Rd)m—N(Ra)C(O)Rb, —(Rd)m—N(Ra)C(O)ORb, —(Rd)m—N(Rc)C(O)NRaRb, —(Rd)m—N(Ra)S(O)2Rb, —(Rd)m—N(Ra)S(O)Rb, —(Rd)m—SRa, —(Rd)m—S(O)Ra, —(Rd)m—S(O)2Ra, —(Rd)m—S(O)NRaRb, —(Rd)m—S(O)2NRaRb, —(Rd)m—O —(Re)m—NRaRb or —(Rd)m—NRa—(Re)—ORb, or R4 and R5 may together cyclize to form a 3-to-5-membered spiro-cycloalkyl;
• wherein any of the said C3-C12 cycloalkyl, aryl, heterocyclyl, or heteroaryl are independently optionally further substituted by 0 to 3 R9 groups;
• R6 is selected from H, Ra—O—Rb, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, —(Rd)m—(C3-C12 cycloalkyl), —(Rd)m-aryl, —(Rd)m-(3-15 membered heterocyclyl), —(Rd)m—(C1-C6 perfluoroalkyl), —(Rd)m-halide, —(Rd)m—CN, —(Rd)m—C(O)Ra, —(Rd)m—C(O)ORa, —(Rd)m—C(O)NRaRb, —(Rd)m—ORa, —(Rd)m—OC(O)Ra, —(Rd)m—OC(O)NRaRb, —(Rd)m—O—S(O)Ra, —(Rd)m—OS(O)2Ra, —(Rd)m—OS(O)2NRaRb, —(Rd)m—OS(O)NRaRb, —(Rd)m—NO2, —(Rd)m—NRaRb, —(Rd)m—N(Ra)C(O)Rb, —(Rd)m—N(Ra)C(O)ORb, —(Rd)m—N(Rc)C(O)NRaRb, —(Rd)m—N(Ra)S(O)2Rb, —(Rd)m—N(Ra)S(O)Rb, —(Rd)m—SRa, —(Rd)m—S(O)Ra, —(Rd)m—S(O)2Ra, —(Rd)m—S(O)NRaRb, —(Rd)m—S(O)2NRaRb, —(Rd)m—O—(Re)m—NRaRb or —(Rd)m—NRa—(Re)—ORb;
• or R6 may together with R4 cyclize to form a 4- to 7-membered heterocyclyl ring fused to the piperazine or piperadine to which they are attached;
• and wherein any of the said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl may independently be further substituted with 0 to 3 R9 groups;
• each R7 and R8 is each independently C1-C2 alkyl, or R7 and R8 together cyclize to form a cyclopropyl or cyclobutyl;
• each R9 is independently selected from H, Ra—O—Rb, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, —(Rd)m—(C3-C12 cycloalkyl), —(Rd)m-aryl, —(Rd)m-(3-15 membered heterocyclyl), —(Rd)m—(C1-C6 perfluoroalkyl), —(Rd)m-halide, —(Rd)m—CN, —(Rd)m—C(O)Ra, —(Rd)m—C(O)ORa, —(Rd)m—C(O)NRaRb, —(Rd)m—ORa, —(Rd)m—OC(O)Ra, —(Rd)m—OC(O)NRaRb, —(Rd)m—O—S(O)Ra, —(Rd)m—OS(O)2Ra, —(Rd)m—OS(O)2NRaRb, —(Rd)m—OS(O)NRaRb, —(Rd)m—NO2, —(Rd)m—NRaRb, —(Rd)m—N(Ra)C(O)Rb, —(Rd)m—N(Ra)C(O)ORb, —(Rd)m—N(Rc)C(O)NRaRb, —(Rd)m—N(Ra)S(O)2Rb, —(Rd)m—N(Ra)S(O)Rb, —(Rd)m—SRa, —(Rd)m—S(O)Ra, —(Rd)m—S(O)2Ra, —(Rd)m—S(O)NRaRb, —(Rd)m—S(O)2NRaRb, —(Rd)m—O—(Re)m—NRaRb or —(Rd)m—NRa—(Re)ORb;
• and wherein any of said alkyl, alkenyl, alkynyl, Rd, Re, C3-C12 cycloalkyl, aryl or 3-15 membered heterocyclyl are independently optionally further substituted by 1-3 groups selected from -halide, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6alkoxyl, C1-C6alkylamino, CN or oxo;
• each Ra, Rb and Rc is independently selected from H, C1-C6 perfluoroalkyl, C1-C8 alkyl, C2-C8 alkenyl, —(C1-C3 alkylene)m-(C3-C8 cycloalkyl), —(C1-C3 alkylene)m-(C3-C8 cycloalkenyl), C2-C8 alkynyl, —(C1-C3 alkylene)m-aryl, or —(C1-C3 alkylene)m-(3-8 member heterocyclyl), and each Ra, Rb and Rc is independently optionally further substituted by 0 to 3 groups selected from halide, hydroxyl, —CN, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 alkoxyl and C1-C6 alkylamino;
• or, when connected to the same nitrogen, Ra and Rb may optionally form a -(3-8 membered heterocyclyl), and said 3-8 membered heterocyclyl is optionally further substituted by 0 to 3 groups selected from halide, hydroxyl, —CN, C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 alkoxyl or C1-C6 alkylamino;
• each Rd and Re is independently —(C1-C3 alkylene)-, —(C2-C5 alkenylene)-, or —(C2-C5 alkynylene)-;
• each m is independently 0 or 1;
• and
• with the proviso that R2, R3, R4 and R5 are not all H.